Burns : journal of the International Society for Burn Injuries · 2026
Analysis of treatment pathways and long-term prevalence of pruritus after burn - An observational study with real-world data.
СтатьяНаблюдательное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kleinhapl Julia, Danielski Lucineia Gainski, Ekale John Nabei, Khalidi Ragheb, McAuley Ryan, Ji Rudy, Mueller Karl, Tripple Julia W, Dempsey Jaclyn, Tran Helen, Branski Ludwik, Golovko George, Wolf Steven E, Finnerty Celeste C
Аннотация
INTRODUCTION: Burns heal with long-lasting scars and complications, such as persistent pruritus. To date, there is no consensus on optimal treatment. This study aims to identify prevalence and treatment patterns of burn-related pruritus using a large dataset.
METHODS: A retrospective cohort study was conducted using the real-world database TriNetX. Burn patients were identified and stratified into three cohorts by extent of total body surface area (TBSA) burned: Cohort 1 (<20 %; mild), Cohort 2 (20-39 %; moderate), and Cohort 3 (≥40 %; severe). Prevalence of pruritus, eosinophilia status, and treatment patterns were assessed. Age group and temporal effects were tested using Chi-square.
RESULTS: We identified 257,360 burn patients with a mean age of 37 ± 23 years. Pruritus prevalence ranged from 3.29 % to 7.95 % in paediatric patients and from 1.50 % to 9.75 % in adult patients. Peak prevalence occurred in those with 20-39 % TBSA burned, aged 41-60 years, and within 3 years after burn. Severe eosinophilia peaked in 41-60-year-olds with burns > 40 % of TBSA. The most commonly prescribed drug classes across all cohorts were H1-antihistamines, 5-HT3 receptor antagonists, and neuropathic pain drugs.
CONCLUSION: Our real-world database analysis indicates that the prevalence of post-burn pruritus varies by age and burn size, showing a tendency to decrease with age but increase over time. The highest prevalence was observed in patients with moderate-sized burns (20-39 % TBSA burned). Treatment patterns remain inconsistent, underscoring the need for standardized and evidence-based strategies.
METHODS: A retrospective cohort study was conducted using the real-world database TriNetX. Burn patients were identified and stratified into three cohorts by extent of total body surface area (TBSA) burned: Cohort 1 (<20 %; mild), Cohort 2 (20-39 %; moderate), and Cohort 3 (≥40 %; severe). Prevalence of pruritus, eosinophilia status, and treatment patterns were assessed. Age group and temporal effects were tested using Chi-square.
RESULTS: We identified 257,360 burn patients with a mean age of 37 ± 23 years. Pruritus prevalence ranged from 3.29 % to 7.95 % in paediatric patients and from 1.50 % to 9.75 % in adult patients. Peak prevalence occurred in those with 20-39 % TBSA burned, aged 41-60 years, and within 3 years after burn. Severe eosinophilia peaked in 41-60-year-olds with burns > 40 % of TBSA. The most commonly prescribed drug classes across all cohorts were H1-antihistamines, 5-HT3 receptor antagonists, and neuropathic pain drugs.
CONCLUSION: Our real-world database analysis indicates that the prevalence of post-burn pruritus varies by age and burn size, showing a tendency to decrease with age but increase over time. The highest prevalence was observed in patients with moderate-sized burns (20-39 % TBSA burned). Treatment patterns remain inconsistent, underscoring the need for standardized and evidence-based strategies.